세계 유전학 유전자 검사 시장 규모는 2023년 247억 8,000만 달러에 달할 것으로 예상됩니다.
이 시장은 2033년까지 819억 5,000만 달러로 급증할 것으로 예상되며, 2024년부터 2033년까지 12.73%의 연평균 복합 성장률(CAGR)을 나타내고, 큰 폭의 성장을 보일 것으로 예상됩니다. 이 시장은 지속적인 기술 발전에 힘입어 두 자릿수 성장률을 기록하고 있습니다. 차세대 염기서열 분석(NGS)과 같은 유전자 염기서열 분석 기술의 혁신으로 유전자 검사의 정확성, 효율성, 비용 효율성이 향상되고 있습니다. 유전성 질환의 진단과 관리를 위한 유전자 검사의 이점에 대한 일반인과 의료 전문가들의 인식이 높아지면서 수요가 증가하고 있습니다. 유전성 질환과 유전성 암의 유병률 증가는 조기 진단과 맞춤 치료 옵션에 대한 필요성을 더욱 부추기고 있습니다. 산전 선별검사, 신생아 선별검사, 종양학, 맞춤의료 등 유전자 검사의 용도가 확대되면서 시장 범위가 넓어지고 있습니다. 규제 당국의 지원과 유리한 가이드라인은 유전자 검사의 품질과 신뢰성을 보장하고 시장 성장을 가속하고 있습니다.
| 주요 시장 통계 | |
|---|---|
| 예측 기간 | 2024-2033년 |
| 2024년 평가 | 278억 8,000만 달러 |
| 2033년 전망 | 819억 5,000만 달러 |
| CAGR | 12.73% |
유전학적 유전자 검사 환경은 전략적 제휴와 혁신적인 기술 발전으로 빠르게 진화하고 있으며, 코니카 미놀타(Konica Minolta, Inc.)가 주도하는 암유전체유전체임상시험연합(INTERACT)과 같은 이니셔티브는 암유전체유전체임상시험의 접근성을 높이는 데 매우 중요한 역할을 합니다. Evidence Coalition(INTERACT) 협업과 같은 이니셔티브는 유전성 암 검사에 대한 접근성을 촉진하는 데 매우 중요하며, Quest Diagnostics Incorporated와 Broad Clinical Labs와 같은 파트너십은 출생 후 발달지연 장애 진단에 있어 전장유전체 염기서열분석(WGS)의 임상적 유용성을 입증하고 있습니다. 또한, 코니카 미놀타(Konica Minolta, Inc., Ambry Genetics)와 템퍼스(Tempus)와의 전략적 제휴와 같이 종합적인 생식세포 및 체세포 검사 서비스 제공이 강화되고 있습니다. 이러한 개발은 Agilent Technologies, Inc.의 GenetiSure Dx Postnatal Assay와 Laboratory Corporation of America Holdings의 pTau217(pTau217) 독립 혈액 바이오마커 Myriad Genetics, Inc.의 Intermountain Precision Genomics 자산 인수와 같은 인수를 통해 업계는 지속적인 성장과 혁신에 박차를 가하고 있습니다. 혁신을 통해 개인화된 유전적 통찰력으로 의료 성과를 향상시킬 수 있는 기반을 마련하고 있습니다.
세계 유전학 유전자 검사 시장은 Agilent Technologies, Ambry Genetics, Color, CENTOGENE N.V., Natera Inc. 등의 기업들에 의해 추진되어 산업 유전학의 전망에 혁명을 일으키고 있습니다. 차세대 염기서열 분석(NGS), 중합효소연쇄반응(PCR), 마이크로어레이 등 첨단 기술을 활용하여 종양 유전학 검사, 신경학 유전학 검사, 심혈관계 유전학 검사, 희귀질환 검사 등에 대응하는 다양한 제품을 제공합니다. 애질런트 테크놀로지스(Agilent Technologies)의 SureMASTR Hereditary Cancer와 같은 종양 조직 기반 검사부터 컬러(Color)가 제공하는 타액 기반 검사에 이르기까지 다양한 제품이 있습니다. 이러한 발전은 연구 및 임상 진단에 영향을 미치고 있으며, 암, 심혈관 질환, 신경 질환, 희귀 유전 질환 등 다양한 질환을 유발하는 유전적 요인에 대한 통찰력을 제공합니다. 첨단 기술과 광범위한 질병 범위의 통합을 통해 세계 유전학 유전자 검사 시장의 산업적 영향력이 커지면서 개인 맞춤형 의료와 유전자 건강 관리의 최전선을 주도하고 있습니다.
이 보고서는 세계 유전학 유전자 검사 시장에 대해 조사했으며, 시장 개요와 함께 제품 유형별/샘플 유형별/기술별/유전자 검사 유형별/응용 분야별/지역별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.
Global Hereditary Genetic Testing Market Industry Overview
The global hereditary genetic testing market, initially valued at $24.78 billion in 2023, is poised for substantial growth, projected to surge to $81.95 billion by 2033, marking a remarkable compound annual growth rate (CAGR) of 12.73% over the period from 2024 to 2033. The market is witnessing double-digit growth, driven by continuous technological advancements. Innovations in genetic sequencing technologies, such as next-generation sequencing (NGS), have made genetic testing more accurate, efficient, and cost-effective. Increased awareness among the public and healthcare professionals about the benefits of genetic testing for diagnosing and managing hereditary conditions has led to higher demand. The rising prevalence of genetic disorders and hereditary cancers further fuels the need for early diagnosis and personalized treatment options. The expanding applications of genetic testing, including prenatal screening, newborn screening, oncology, and personalized medicine, are broadening the market scope. Regulatory support and favorable guidelines ensure the quality and reliability of genetic tests, facilitating market growth.
Market Introduction
| KEY MARKET STATISTICS | |
|---|---|
| Forecast Period | 2024 - 2033 |
| 2024 Evaluation | $27.88 Billion |
| 2033 Forecast | $81.95 Billion |
| CAGR | 12.73% |
The landscape of hereditary genetic testing is rapidly evolving, fuelled by strategic collaborations and innovative advancements in technology. Initiatives such as the Inter-Organization Cancer Genetics Clinical Evidence Coalition (INTERACT) Collaboration, led by Konica Minolta, Inc. (Ambry Genetics), are pivotal in promoting access to hereditary cancer testing, while partnerships such as that between Quest Diagnostics Incorporated and Broad Clinical Labs are demonstrating the clinical utility of whole genome sequencing (WGS) for diagnosing developmental delay disorders post-birth. Moreover, strategic alliances such as the one between Konica Minolta, Inc. (Ambry Genetics) and Tempus are enhancing the provision of comprehensive germline and somatic testing services. These developments are complemented by product approvals and launches, such as Agilent Technologies, Inc.'s GenetiSure Dx Postnatal Assay and Laboratory Corporation of America Holdings' independent blood biomarker test for phosphorylated tau 217 (pTau217), each contributing to the expanding toolkit of genetic testing options. With acquisitions such as Myriad Genetics, Inc.'s acquisition of assets from Intermountain Precision Genomics, the industry is poised for sustained growth and innovation, promising improved healthcare outcomes through personalized genetic insights.
Industrial Impact
The global hereditary genetic testing market, propelled by companies such as Agilent Technologies, Ambry Genetics, Color, CENTOGENE N.V., Natera Inc., Myriad Genetics, Inc., and Illumina, Inc., has revolutionized the landscape of industrial genetics. By utilizing advanced technologies such as next-generation sequencing (NGS), polymerase chain reaction (PCR), and microarray, these companies offer a wide array of products catering to oncology genetic testing, neurology genetic testing, cardiology genetic testing, and rare disease testing, among others. These products range from tumor tissue-based tests such as SureMASTR Hereditary Cancer by Agilent Technologies to saliva-based tests such as those offered by Color. The impact of these advancements extends across research and clinical diagnostics, offering insights into hereditary factors contributing to various diseases such as cancer, cardiovascular disorders, neurological conditions, and rare genetic diseases. Through the integration of cutting-edge technologies and expansive disease coverage, the industrial impact of the global hereditary genetic testing market is profound, driving forward the frontiers of personalized medicine and genetic healthcare.
Market Segmentation:
Segmentation 1: by Product
Services Segment to Dominate the Hereditary Genetic Testing Market (by Product)
Based on product, the global hereditary genetic testing market was led by the services segment, which held a 69.33% share in 2023. This substantial market share indicates the high demand for services related to hereditary genetic testing, which includes genetic counseling, testing, and result interpretation. The prominence of the services segment highlights the importance of comprehensive support and expertise in genetic testing processes, ensuring accurate diagnosis and personalized healthcare solutions.
Segmentation 2: by Sample Type
Blood Segment to Dominate the Hereditary Genetic Testing Market (by Sample Type)
Based on sample type, the global hereditary genetic testing market was led by the blood segment, which held a 41.79% share in 2023. This dominant market share underscores the preference for blood samples in hereditary genetic testing due to their reliability and ease of collection. Blood samples provide a rich source of DNA, which is essential for accurate and comprehensive genetic analysis. The prominence of the blood segment reflects the established protocols and widespread acceptance of blood-based testing in clinical and research settings. This trend highlights the crucial role of blood samples in facilitating precise diagnosis and management of hereditary conditions, ultimately contributing to improved patient care and outcomes.
Segmentation 3: by Technology
Next-Generation Sequencing Segment to Dominate the Hereditary Genetic Testing Market (by Technology)
Based on technology, the global hereditary genetic testing market was led by the next-generation sequencing segment, which held a 32.08% share in 2023. This significant market share highlights the advanced capabilities and growing adoption of NGS technology in hereditary genetic testing. NGS offers high-throughput sequencing, enabling the rapid and comprehensive analysis of multiple genes simultaneously, which is crucial for identifying a wide range of genetic mutations associated with hereditary conditions. The prominence of the NGS segment reflects its efficiency, accuracy, and cost-effectiveness, making it the preferred choice for both clinical diagnostics and research applications. This trend underscores the transformative impact of NGS on the genetic testing landscape, driving innovations and improving the detection and management of hereditary diseases.
Segmentation 4: by Oncology Genetic Testing Type
Breast Cancer Segment to Dominate the Hereditary Genetic Testing Market (by Oncology Genetic Testing Type)
Based on oncology genetic testing type, the global hereditary genetic testing market was led by the breast cancer segment, which held a 41.97% share in 2023. This significant market share underscores the high demand for genetic testing for breast cancer, reflecting the critical importance of early detection and risk assessment in managing this prevalent condition. Genetic testing for breast cancer, particularly for BRCA1 and BRCA2 mutations, plays a crucial role in identifying individuals at higher risk, enabling preventive measures and personalized treatment strategies.
Segmentation 5: by Cardiology Genetic Testing Type
Cardiomyopathy Segment to Dominate the Hereditary Genetic Testing Market (by Cardiology Genetic Testing Type)
Based on cardiology genetic testing type, the global hereditary genetic testing market was led by the cardiomyopathy segment, which held a 33.47% share in 2023. This substantial market share underscores the growing recognition of the importance of genetic testing in diagnosing and managing cardiomyopathies, which are often hereditary and can lead to severe cardiac conditions if not detected early. Genetic testing for cardiomyopathies helps identify specific genetic mutations that cause various forms of the disease, facilitating early intervention, personalized treatment plans, and better management of at-risk individuals.
Segmentation 6: by Neurology Genetic Testing Type
Epilepsy Segment to Dominate the Hereditary Genetic Testing Market (by Neurology Genetic Testing Type)
Based on neurology genetic testing type, the global hereditary genetic testing market was led by the epilepsy segment, which held a 35.55% share in 2023. This significant market share highlights the critical role of genetic testing in diagnosing and managing epilepsy, a neurological disorder with various hereditary forms. Genetic testing for epilepsy helps identify specific genetic mutations that can influence the condition, enabling more accurate diagnoses and the development of personalized treatment plans. The dominance of the epilepsy segment reflects the growing importance of genetic insights in understanding the underlying causes of epilepsy, leading to improved patient care and outcomes.
Segmentation 7: by Other Genetic Testing Type
Rare Disease Testing Segment to Dominate the Hereditary Genetic Testing Market (by Other Genetic Testing Type)
Based on other genetic testing type, the global hereditary genetic testing market was led by the rare disease testing segment, which held a 39.13% share in 2023. This substantial market share highlights the crucial role of genetic testing in diagnosing rare diseases, which often have a hereditary component. Genetic tests for rare diseases are essential for identifying specific mutations that may not be well understood or easily diagnosed through traditional methods. The dominance of the rare disease testing segment reflects the growing awareness and need for precise diagnostic tools to manage and treat these conditions effectively.
Segmentation 8: by Application Area
Clinical Diagnostics Segment to Dominate the Hereditary Genetic Testing Market (by Application Area)
Based on application area, the global hereditary genetic testing market was led by the clinical diagnostics segment, which held a 40.99% share in 2023. This substantial market share highlights the crucial role of clinical diagnostics in hereditary genetic testing, emphasizing the importance of accurate and early detection of genetic conditions for effective medical intervention. The dominance of the clinical diagnostics segment reflects the growing reliance on genetic tests to guide clinical decisions and personalize treatment plans, ultimately improving patient outcomes. This trend underscores the significance of integrating advanced genetic diagnostics into routine clinical practice to address the rising prevalence of hereditary disorders and enhance healthcare delivery.
Segmentation 9: by Region
The hereditary genetic testing market in the North America region is expected to witness a significant growth rate of 11.41% during the forecast period. This notable growth can be attributed to several key factors. Continuous advancements in genetic testing technologies are enhancing the accuracy and accessibility of hereditary genetic tests, driving market expansion. Growing awareness about the importance of genetic testing for early diagnosis and management of inherited conditions is leading to higher adoption rates among healthcare providers and patients. Supportive government policies and funding for genetic research and testing are fostering a conducive environment for market growth in the region. However, the Asia-Pacific region is expected to reach $21.97 billion in 2033 from $5.36 billion in 2023, at a CAGR of 15.18% during the forecast period 2024-2033.
Recent Developments in the Hereditary Genetic Testing Market
Demand - Drivers, Challenges, and Opportunities
Market Drivers:
Rising Prevalence of Genetic Disorders along with Rare Diseases: Genetic diseases stem from abnormalities within an individual's DNA. They can arise through inheritance from one or both parents or manifest due to spontaneous genetic mutations. These conditions may result from a mutation in a single gene (monogenic), a chromosomal alteration involving an abnormal number of copies, or complex disorders influenced by the combined effects of multiple genes (polygenic). Next-generation sequencing techniques are widely used for the diagnosis of genetic diseases. Increasing widespread use of NGS in diagnostic laboratories has enhanced the accuracy of genetic diagnostics with high consistency.
Market Challenges:
Privacy and Ethical Concerns Due to Increased Risk of Security Breaches: Privacy and ethical concerns have become significant challenges in the hereditary genetic testing market, especially with the increasing risk of security breaches. As genetic data contain detailed personal information, they have become a prime target for cyberattacks. The implications of such breaches are profound, considering the sensitivity of genetic information, which can reveal predispositions to certain diseases and other personal attributes.
Market Opportunities:
Rise of Direct-to-Consumer (DTC) Testing Services: The increasing number of direct-to-consumer (DTC) hereditary genetic tests is set to significantly influence the global hereditary genetic testing market. As defined by the U.S. FDA, DTC tests allow consumers to bypass traditional healthcare systems by sending specimens directly to testing companies. This accessibility is appealing as it eliminates many of the barriers associated with traditional genetic testing, such as the need for a healthcare provider's referral, potentially lengthy wait times, and sometimes prohibitive costs. Companies such as 23andMe have pioneered this approach, becoming the first to obtain FDA approval for such tests, signaling a robust regulatory framework that supports consumer safety while encouraging innovation.
How can this report add value to an organization?
Product/Innovation Strategy: The global hereditary genetic testing market has been extensively segmented based on various categories, such as technology, product, sample type, application area, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.
Growth/Marketing Strategy: Partnerships, alliances, and collaborations accounted for the maximum number of key developments, i.e., nearly 37.14% of the total developments in the global hereditary genetic testing market were between January 2020 and April 2024.
Competitive Strategy: The global hereditary genetic testing market has numerous established players with product portfolios. Key players in the global hereditary genetic testing market analyzed and profiled in the study involve established players offering products for hereditary genetic testing.
Methodology
Key Considerations and Assumptions in Market Engineering and Validation
Primary Research:
The primary sources involve industry experts in hereditary genetic testing, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.
The key data points taken from the primary sources include:
Secondary Research
Open Sources
The key data points taken from the secondary sources include:
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Some prominent names established in this market are:
Scope and Definition